These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20549152)

  • 21. CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate.
    Kondrasenko AA; Goncharov EV; Dugaev KP; Rubaylo AI
    Forensic Sci Int; 2015 Dec; 257():209-213. PubMed ID: 26386336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current state of so-called "chemical drug"--difference between display name and content element].
    Kojima T
    Chudoku Kenkyu; 2005 Jan; 18(1):83-5. PubMed ID: 15844371
    [No Abstract]   [Full Text] [Related]  

  • 23. Contamination of clandestinely prepared drugs with synthetic by-products.
    Soine WH
    NIDA Res Monogr; 1989; 95():44-50. PubMed ID: 2701314
    [No Abstract]   [Full Text] [Related]  

  • 24. Prediction of cytochrome p450 mediated metabolism of designer drugs.
    Nielsen LM; Linnet K; Olsen L; Rydberg P
    Curr Top Med Chem; 2014; 14(11):1365-73. PubMed ID: 24805063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designer drugs: a medicinal chemistry perspective.
    Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA
    Ann N Y Acad Sci; 2012 Feb; 1248():18-38. PubMed ID: 22092008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-residue analysis of eight thioamphetamine designer drugs in human urine by liquid chromatography/tandem mass spectrometry.
    Nieddu M; Boatto G; Pirisi MA; Baralla E
    Rapid Commun Mass Spectrom; 2009 Oct; 23(19):3051-6. PubMed ID: 19705383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis.
    Swortwood MJ; Boland DM; DeCaprio AP
    Anal Bioanal Chem; 2013 Feb; 405(4):1383-97. PubMed ID: 23180084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designer steroids.
    Kazlauskas R
    Handb Exp Pharmacol; 2010; (195):155-85. PubMed ID: 20020364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.
    Peters FT; Schaefer S; Staack RF; Kraemer T; Maurer HH
    J Mass Spectrom; 2003 Jun; 38(6):659-76. PubMed ID: 12827635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heavy metal and organic contaminants associated with illicit methamphetamine production.
    Burton BT
    NIDA Res Monogr; 1991; 115():47-59. PubMed ID: 1758482
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolism of designer drugs of abuse.
    Staack RF; Maurer HH
    Curr Drug Metab; 2005 Jun; 6(3):259-74. PubMed ID: 15975043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designer psychostimulants in urine by liquid chromatography-tandem mass spectrometry.
    Kerrigan S; Mott A; Jatzlau B; Ortiz F; Perrella L; Martin S; Bryand K
    J Forensic Sci; 2014 Jan; 59(1):175-83. PubMed ID: 24313279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The detection of NBOMe designer drugs on blotter paper by high resolution time-of-flight mass spectrometry (TOFMS) with and without chromatography.
    Botch-Jones S; Foss J; Barajas D; Kero F; Young C; Weisenseel J
    Forensic Sci Int; 2016 Oct; 267():89-95. PubMed ID: 27572638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brephedrone: A new psychoactive substance seized in Brazil.
    Machado Y; Coelho Neto J; Barbosa PEN; Lordeiro RA; Alves RB
    Forensic Sci Int; 2017 Jun; 275():302-307. PubMed ID: 28445860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FAPA mass spectrometry of designer drugs.
    Smoluch M; Gierczyk B; Reszke E; Babij M; Gotszalk T; Schroeder G; Silberring J
    Talanta; 2016; 146():29-33. PubMed ID: 26695230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of collision-induced dissociation of electrospray-generated protonated cathinones.
    Fornal E
    Drug Test Anal; 2014; 6(7-8):705-15. PubMed ID: 24259394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ecstasy and neurodegeneration. Tablets often contain substances in addition to, or instead of, ecstasy..
    Winstock AR; King LA
    BMJ; 1996 Aug; 313(7054):423-4. PubMed ID: 8761240
    [No Abstract]   [Full Text] [Related]  

  • 38. Identification of a cannabinoid analog as a new type of designer drug in a herbal product.
    Uchiyama N; Kikura-Hanajiri R; Kawahara N; Haishima Y; Goda Y
    Chem Pharm Bull (Tokyo); 2009 Apr; 57(4):439-41. PubMed ID: 19336947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging trends in the abuse of designer drugs and their catastrophic health effects: update on chemistry, pharmacology, toxicology and addiction potential.
    Rapaka RS; Purohit V; Schnur P; Rutter J
    Life Sci; 2014 Feb; 97(1):1. PubMed ID: 24529194
    [No Abstract]   [Full Text] [Related]  

  • 40. Analysis of a new drug of abuse: cathinone derivative 1-(3,4-dimethoxyphenyl)-2-(ethylamino)pentan-1-one.
    Weiß JA; Taschwer M; Kunert O; Schmid MG
    J Sep Sci; 2015 Mar; 38(5):825-8. PubMed ID: 25545103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.